Difference between revisions of "Part:BBa K3885222"
(→Characterization) |
(→Characterization) |
||
Line 18: | Line 18: | ||
} | } | ||
</style> | </style> | ||
− | <div class="flex" style="margin: 0 auto;width: 100%;"> | + | <div class="flex" style="margin: 0 auto; style="border: 1px solid #000; width: 100%;"> |
<div> | <div> | ||
<img src="https://static.igem.org/mediawiki/parts/9/98/222_NUPANK-1.png" width="350" style="display: block;margin: 10px auto;"/> | <img src="https://static.igem.org/mediawiki/parts/9/98/222_NUPANK-1.png" width="350" style="display: block;margin: 10px auto;"/> |
Revision as of 17:13, 17 October 2021
J23119-CXCL9
The short version of DNA sequence coding for CXCL9 mRNA can be expressed under the control of a strong promoter J23119.
Usage and Biology
1.This plamsid can transfer CXCL9 mRNA. CXCL9 mRNA is a biomarker, based on the final intensity of the fluorescence, we can know if a person is sick.
2.It can be used in other experiments for disease markers.
Characterization
![](https://static.igem.org/mediawiki/parts/9/98/222_NUPANK-1.png)
![](https://static.igem.org/mediawiki/parts/b/b6/222_EMSA.png)
Figure 7. Polyacrylamide gel-shift assay analysis of the igRNA hybridizating with CXCL9 mRNA.
It can transfer CXCL9 mRNA to combine with the complex of igRNA and Cas9 protein. Then they can perform cutting function. And they can cut tetR of P70-σ28-P28-tetR to express fluorescence of P28-tetO-deGFP.We know from experiments that the dCas9-igRNA complex which combined with CXCL9 has higher fluorescence intensity.
Design Page
CXCL9 mRNA, a biomarker indicative of rejection in renal-transplant recipients. We found that existing techniques for detecting rejection in kidney transplantation can not be used to detect disease in a non-invasive manner. And CRISPR-Cas has the potential to detect disease.So we use CRISPR-Cas9 to verify if this system can detect CXCL9 mRNA or other biomarkers.
References
Kaminski Michael M et al. A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection.[J]. Nature biomedical engineering, 2020, 4(6) : 601-609.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 7
Illegal NheI site found at 30 - 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]